Fort Sheridan Advisors’s Intellia Therapeutics NTLA Stock Holding History

Fort Sheridan Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,478	Closed	-$206K	–	239
2024 Q1	$206K	Sell	7,478 -199	-3%	-$5.53K	0.04%	194
2023 Q4	$234K	Buy	7,677 +357	+5%	+$10.3K	0.05%	173
2023 Q3	$231K	Hold	7,320	–	–	0.05%	168
2023 Q2	$299K	Hold	7,320	–	–	0.07%	151
2023 Q1	$273K	Buy	7,320 +400	+6%	+$15.7K	0.07%	159
2022 Q4	$241K	Hold	6,920	–	–	0.08%	155
2022 Q3	$387K	Hold	6,920	–	–	0.13%	115
2022 Q2	$358K	Buy	6,920 +1,260	+22%	+$64K	0.12%	120
2022 Q1	$411K	Hold	5,660	–	–	0.12%	112
2021 Q4	$669K	Hold	5,660	–	–	0.19%	87
2021 Q3	$759K	Hold	5,660	–	–	0.25%	74
2021 Q2	$916K	Hold	5,660	–	–	0.31%	57
2021 Q1	$454K	Buy	5,660 +59	+1%	+$3.96K	0.18%	84
2020 Q4	$305K	Buy	+5,601	New	+$203K	0.15%	92

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fort Sheridan Advisors's NTLA Position: Q2 2024 in Review

Fort Sheridan Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 7,478 shares — an estimated $206K sold.

Fort Sheridan Advisors first reported a position in NTLA in Q4 2020 and held it in 14 quarters. The position peaked at $916K in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

Fort Sheridan Advisors reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
Fort Sheridan Advisors sold 7,478 Intellia Therapeutics shares in Q2 2024, an estimated $206K.
Fort Sheridan Advisors first reported a position in Intellia Therapeutics in Q4 2020 and held it in 14 quarters.
Fort Sheridan Advisors's Intellia Therapeutics position peaked at $916K in Q2 2021.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on Fort Sheridan Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.